tirzepatide for metabolic dysfunction Emerging Role of GLP-1 Receptor Agonists the Treatment of MASH Major physiological roles of GLP-1

The 39-amino acid peptide is built on a GIP backbone (not GLP-1), with approximately 5-fold higher affinity for the GIP receptor than native GIP and reduced but clinically meaningful affinity for the GLP-1 receptor

Highlights of prescribing information: Zepbound (tirzepatide) injection, for subcutaneous use

Research shows Zepbound supports average weight loss of around 25% after one year and 16% on Wegovy

General peptide calculator - Works for tirzepatide and any other peptide

Users who experience aches during the first few weeks and then see them resolve typically also report strong appetite suppression and steady weight loss during that same period

Drucker, D